Adverse effects in hospice patients with chronic kidney disease receiving hydromorphone

Journal of Palliative Medicine

Volumn 14, Issue 9, 2011, Pages 1029-1033

  Paramanandam, Gobi ^a   Prommer, Eric ^b   Schwenke, Dawn C ^c  

^a Center for Pain and Supportive Care   (United States)

^b MAYO CLINIC   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROMORPHONE;

ADULT; AGED; AGITATION; CHRONIC KIDNEY FAILURE; CHRONIC PAIN; COGNITIVE DEFECT; CONTINUOUS INFUSION; DRUG DOSE INCREASE; FEMALE; GLOMERULUS FILTRATION RATE; HOSPICE PATIENT; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MYOCLONUS; NERVE CELL STIMULATION; REVIEW; SEIZURE; SIDE EFFECT; TREATMENT DURATION; TREMOR;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; ARIZONA; FEMALE; GLOMERULAR FILTRATION RATE; HOSPICE CARE; HUMANS; HYDROMORPHONE; KIDNEY FAILURE, CHRONIC; MALE; MEDICAL AUDIT; MIDDLE AGED; NEURONS; STIMULATION, CHEMICAL; YOUNG ADULT;

EID: 80052713653     PISSN: 10966218     EISSN: 15577740     Source Type: Journal    
DOI: 10.1089/jpm.2011.0103     Document Type: Review

References (15)

1. Micromedex healthcare online. www.micromedex.com (Last accessed November 12, 2009.
2. Hagen N, Thirlwell MP, Dhaliwal HS, Babul N, Harsanyi Z, Darke AC: Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. J Clin Pharmacol 1995;35:37.
3. Wright AWE, Mather LE, Smith MT: Hydromorphone-3- glucuronide: A more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci 2001;69:409-420.
4. Babul N, Darke AC, Hagen N: Hydromorphone metabolite accumulation in renal failure. J Pain Sympt Manage 1995; 10:184.
5. Babul N, Darke AC: Putative role of hydromorphone metabolites in myoclonus. Pain 1992;51:260-261.
6. Hagen N, Swanson R: Multifocal myoclonus and seizures in extremely high dose opioid administration. Neurology 1993;43.
7. Fainsinger R, Schoeller T, Boiskin M, Bruera E: Palliative care round: Cognitive failure and coma after renal failure in a patient receiving captopril and hydromorphone. J Palliat Care 1993;9:53.
8. MacDonald N, Der L, Allan S, Champion P: Opioid hyperexcitability: The application of alternate opioid therapy. Pain 1993;53:353-355.
9. Eisele JH: Clonazepam treatment of myoclonic contractions associated with high-dose opioids: Case report. Pain 1992; 49:231-232.
10. Lee MA, Leng MEF, Tiernan EJJ: Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med 2001;15:26.
11. Davison SN, Mayo PR: Pain management in chronic kidney disease: The pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3- glucuronide in hemodialysis patients. J Opioid Manage 2008;4:335.
12. Thwaites D, McCann S, Broderick P: Hydromorphone neuroexcitation. J Palliat Med 2004;7:545-550.
13. Lawlor PG: The panorama of opioid related cognitive dysfunction in patients with cancer. Cancer 2002;94:1836-1853.
14. Malyszko J, Przybylowski P, Malyszko JS, Iaina-Levin N, Sadowski J, Mysliwiec M: Prevalence of chronic kidney disease in orthotopic heart transplant recipients and kidney allograft recipients using the new Chronic Kidney Disease Epidemiology Collaboration Formula. Transplantation Proc 2010;42:4251-4254.
15. Mercadante S, Portenoy RK: Opioid poorly-responsive cancer pain. Part 1: Clinical Considerations. J Pain Sympt Manage 2001;21:144-150.